PRC
CYTK icon

Pearl River Capital’s Cytokinetics CYTK Stock Holding History

Pearl River Capital’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-4,839
Closed -$262K – 103
2024
Q2 		$262K Buy
+4,839
New +$292K 0.04% 366
2022
Q4 		– Sell
-5,341
Closed -$259K – 520
2022
Q3 		$259K Buy
+5,341
New +$257K 0.05% 399

Other funds holding CYTK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Pearl River Capital's CYTK Position: Q3 2024 in Review

Pearl River Capital sold out of Cytokinetics (CYTK) in Q3 2024, closing a stake of 4,839 shares — an estimated $262K sold.

Pearl River Capital first reported a position in CYTK in Q3 2022 and held it in 2 quarters. The position peaked at $262K in Q2 2024. 347 funds tracked by Wall St. Rank hold CYTK as of Q3 2024.

  • Pearl River Capital reported no remaining Cytokinetics position as of Q3 2024 after selling out during the quarter.
  • Pearl River Capital sold 4,839 Cytokinetics shares in Q3 2024, an estimated $262K.
  • Pearl River Capital first reported a position in Cytokinetics in Q3 2022 and held it in 2 quarters.
  • Pearl River Capital's Cytokinetics position peaked at $262K in Q2 2024.
  • 347 funds tracked by Wall St. Rank held Cytokinetics as of Q3 2024.

Based on Pearl River Capital's 13F filing for Q3 2024.